Luminex Corp (LMNX)

When the overly optimistic FOMC says that household spending will be "constrained" by sluggish income growth, ongoing job losses, lower household wealth, and tight credit AND Shanghai stocks hit a seven-week low, then you know this bear market rally is finally over!

A small company with a market cap bellow 1 billion who sits at the center of an industry with its flow cytometry patents and technology. The list of their partners is truely impressive. This is a platform technology company who licences its tech to so many companies that it's difficult to keep track. Luminex is extremely well positioned to ride the wave of diagnostic upgrades that our medical system will eventually need to do. Many of the clinical tests we do are time consuming, labour intensive and slow. The current uncertainty in the health care market makes short term predictions about this and so many other diagnostic companies difficult but the significant funds unlocked as part of the stimulus package will certainly be a big accelerator for the research market that Luminex serves. The market seems to have partailly priced in the effect of the stimulus package for companies like Illumina, Life, Affymetrix and Luminex but might have overlooked the long term advantage that first movers can have in science diagnostics. Companies that are well positioned to sell their machines now might be 'locking in' for a significant amount of time. Their research platforms could become standards for a relatively long time. Research plateforms could also become stepping stones to the clinical market.